Enhancing Predictability: Advanced Translational Models
Oncology researchers frequently struggle with the poor predictability of standard cell lines and traditional xenografts, leading to high attrition rates in clinical trials because these models fail to accurately reflect human tumor biology and clinical response. To address this problem, Crown Bioscience's solution provides:- Clinically Relevant Models
We use patient-derived xenograft (PDX) and patient-derived organoid (PDO) models which retain the genetic and histological heterogeneity of the original human tumor. - Predictive Trial Design
Our Mouse Clinical Trial (MCT™) platform leverages large cohorts of PDX models to mimic human clinical trial design, providing statistically powerful, predictive data on drug efficacy and patient segmentation. - Translational Insight
By correlating preclinical data from these advanced models with human clinical outcomes, we offer a more reliable translational bridge, significantly de-risking your clinical development program and identifying potential responsive patient populations earlier.
PDX Mouse Clinical Trials: Bridging Preclinical and Clinical Oncology Research
PDX MCTs from Crown Bioscience provide a predictive, clinically relevant platform for oncology drug development. By preserving the genetic and phenotypic profile of the original human tumor, our PDX models enable researchers to bridge preclinical studies and clinical success—reducing attrition, accelerating biomarker discovery, and guiding more effective treatment strategies.
Crown Bioscience's PDX MCTs, formerly known as HuTrial, are designed to bridge the gap between preclinical studies and clinical success, offering a reliable pathway to more accurate predictions and outcomes. Our services provide a comprehensive solution for drug developers seeking to optimize their pipelines, validate biomarkers, and reduce the risk of clinical attrition.
Benefits of Patient-Derived Xenograft Mouse Clinical Trials
PDX MCT trials are used primarily to generate more predictive and clinically relevant data than traditional preclinical models. However, there are many other reasons to utilize this powerful assay, which:
PDX MCTs use a large panel of patient-derived xenograft models, each representing a unique patient's tumor. This design allows researchers to study a drug's effect across a diverse patient population, similar to a real-world clinical trial.
By testing a drug across a wide variety of PDX models, researchers can clearly distinguish between responding and non-responding tumors. This is crucial for developing personalized medicine strategies and defining the specific patient population that will benefit most from the treatment.
MCTs provide a powerful platform for identifying and validating predictive biomarkers. Researchers can analyze the genomic, proteomic, and spatial data from the responding and non-responding tumors to discover the molecular signatures that correlate with drug efficacy.
The comprehensive data generated from MCTs—including multiomics analysis, spatial biology, and advanced statistical modeling—provides a deeper understanding of a drug's mechanism of action (MoA) and potential resistance pathways.
The high failure rate of oncology drugs in clinical trials is often due to a lack of efficacy. By using PDX MCTs, researchers can generate robust preclinical data that more accurately predicts clinical outcomes.
Delivering Comprehensive Solutions in
PDX Mouse Clinical Trials
Our PDX Mouse Clinical Trials are designed to maximize the impact of your oncology research by offering:
- Optimized clinical trial designs tailored to maximize predictive power and ensure clinical relevance, setting your studies up for success in oncology drug development.
- Integrated data reports that combine biomarker discovery, PK/PD analysis, and bioinformatics to provide a holistic view of your study's outcomes.
- Seamless service, from trial initiation to final report—our dedicated team ensures consistency, quality, and efficiency at every stage, empowering you to confidently advance in your drug development journey.
